6 recruiting, 3 withdrawn, 2 completed, 1 active not recruiting. 6 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Withdrawn 3, Recruiting 2, Completed 1 |
| Phase 2 | 5 | Recruiting 3, Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Xospata: new trials by email Literature Review of Xospata trials Research Report on Xospata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1 | Phase 1 | Recruiting | Kura Oncology, Inc. | 171 | 2024-02-22 | 2026-08-20 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Ayman H Qasrawi | 2023-03-01 | 2023-04-25 | |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation Gilteritinib Exposure - Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation | Completed | Astellas Pharma Korea, Inc. | 33 | 2022-06-17 | 2025-05-31 | |
| Real World Outcomes Using Novel Agents for AML in the UK Venetoclax, Gilteritinib - Acute Myeloid Leukemia | Unknown | Guy's and St Thomas' NHS Foundation Trust | 1000 | 2022-05-01 | 2023-03-02 | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies ERAS-007, ERAS-601, Gilteritinib - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Erasca, Inc. | 2022-03-15 | 2022-06-15 | |
| Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML Venetoclax, Decitabine for Injection, Cytarabine - AML, Adult, Chemotherapy Effect | Phase 3 | Active not recruiting | Chen Suning | 188 | 2022-03-01 | 2024-10-03 |
| Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Gilteritinib, Vyxeos - Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2022-02-25 | 2025-12-05 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. Gilteritinib, Idarubicin, Cytarabine - Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Astellas Pharma Inc | 97 | 2015-02-26 | 2025-09-02 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
Leukemia, Myeloid, Acute (12) · Recurrence (3) · Blast Crisis (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Myelodysplastic Syndromes (1) · Neoplasms by Histologic Type (1)
Astellas Pharma Inc (1) · Astellas Pharma Korea, Inc. (1) · Ayman H Qasrawi (1) · Chen Suning (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Erasca, Inc. (1) · French Innovative Leukemia Organisation (1) · Guy's and St Thomas' NHS Foundation Trust (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kura Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (8) · South Korea (2) · Australia (1) · Canada (1) · China (1) · France (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Ayman Qasrawi, MD (1) · Guido Marcucci (1) · Hiroto Inaba, MD, PhD (1) · Les Brail, Ph.D. (1) · Onyee Chan, MD (1) · Richard Dillon (1) · Tapan M Kadia (1) · Todd M Cooper (1)
PMID 29702001, PMID 33843815, PMID 34329576, PMID 36892565, PMID 38107263, PMID 38947228, PMID 40009498, PMID 40193193, PMID 40500616, PMID 41835842, PMID 42497367
P30CA033572 (1), U10CA180886 (1)